Fidelis Care Authorization Grids Effective February 1, 2023
12/29/2022
•
Posted by Provider Relations
in
Provider News
The following sections of the Fidelis Care authorization grids have been updated effective February 1, 2023.
The Medicaid grid has been updated as follows:
C. Home Health Care: Home care approvals are based on the medical need for skilled services.
- Personal Care Services for Medicaid and Managed Long Term Care (MLTC-Fidelis Care at Home and MAP). All services require authorization and use of the following codes:
|
Service Description
|
HCPCS Code
|
Service Billing Units
|
|
Level II Mutual Case (multiple)
|
T1019U3
|
Per 15 mins
|
|
Level II Shared Aide (up to two)
|
T1019U2
|
Per 15 mins
|
|
Level II-Hard to Serve
|
T1019U4
|
Per 15 mins
|
|
Live In Level II
|
T1020
|
Per Diem (1 unit per day)
|
|
Live In Level II Mutual Case (multiple)
|
T1020U2
|
Per Diem (1 unit per day)
|
|
Live In Level II - Two Client Hard to Serve
|
T1020U5
|
Per Diem (1 unit per day)
|
- Consumer Directed Personal Assistance services (CDPAS) is a benefit for Medicaid and Medicare and requires authorization.
|
Service Description
|
HCPCS Code
|
Service Billing Units
|
|
Consumer Direct 1 Client
|
T1019U6
|
Per 15 mins
|
|
Consumer Direct 2 Client
|
T1019U7
|
Per 15 mins
|
|
Consumer Direct 1 Client Enhanced
|
T1019U8
|
Per 15 mins
|
|
Consumer Direct 2 Client Enhanced
|
T1019U9
|
Per 15 mins
|
|
Consumer Direct Live In 1 Client
|
T1020U6
|
Per Diem (1 unit per day)
|
|
Consumer Direct Live In 2 Client
|
T1020U7
|
Per Diem (1 unit per day)
|
New Century Health (NCH) will require review of the following codes as of 02/01/2023:
Added to the list of drugs that require NCH review for Medicaid, Essential Plan and Metal-level products:
- J0893 Decitabine (SUN PHARMA) Injection
- J8999 Olutasidenib oral
Added to the list of drugs that require NCH review for Medicare:
- J0893 Decitabine (SUN PHARMA) Injection (DACOGEN) – Medicare Part B and D
- J8999 Olutasidenib (REZLIDHIA) –Medicare Part D only
The following codes have been updated on the Essential Plan grid and require prior authorization:
- J0219 avalglucosidase alfa-ngpt
- J0741 cabotegravir and rilpivirine inj
The following codes have been updated on the Medicare grid and require prior authorization:
- J0893 decitabine (Dacogen)
- J1453 fosaprepitant (Emend)
- J9041 bortezomib (Velcade)
- J9395 fulvestrant (Faslodex)
- Q0510 Pharmacy supply fee for initial immunosuppressive drug(s)
- Q0511 Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period
- Q0512 Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
- Q0513 Pharmacy dispensing fee for inhalation drug(s); per 30 days
- Q0514 Pharmacy dispensing fee for inhalation drug(s); per 90 days
The following codes have been updated on the Metal-Level grid and require prior authorization:
- C9094 sutimlimab-jome
- J0219 avalglucosidase alfa-ngpt
- J9298 nivolumab and relatlimab-rmbw (Opdualag)
Visit: Authorization Grids
COVID-19 UPDATE: Please refer to this link: Important Updates Regarding Coronavirus COVID-19, for authorization and coding guidelines related to the COVID-19 Pandemic.